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EBRT may be
superior, but
Non-inferiority is
established
EBRT may be superior, but
Non-inferiority is plausible
EBRT is superior.
Non-inferiority
not plausible
TARGIT non-Inferiority is
plasusible.
EBRT is not superior
TARGIT non-Inferiority is established.TARGIT is
superior
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Fig. 1. The meaning of non-inferiority: 10 examples of different scenarios that might occur in a randomized trial testing
noninferiority between 2 treatments. The dots represent the absolute difference; the lines represent the confidence intervals.
The green circle includes 2 of the trial results: on the left is the targeted intraoperative radiation therapy (TARGIT) pre-
pathology stratum (difference 0.37%), and on the right is the earliest cohort of the whole trial (nZ1222), which has the
median follow-up time of 5 years (difference 1.14%) (see Table 3 of the main report) (1, 2).
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There has been a divergence of attitudes to the results of the
targeted intraoperative radiation therapy (TARGIT)-A trial
(1, 2). In Europe and Asia, TARGIT-IntraOperative
RadioTherapy (IORT) is now being included in national
guidelines and is available in over 250 centers worldwide.
In the United States, too, it is available in more than 60
centers; yet, it has repeatedly been subjected to fierce
criticism by the same set of individuals. A recent editorial
in this journal by Hepel and Wazer (3) exemplifies the
latter, and we believe it necessary to address their several
conceptual, scientific, and factual inaccuracies.20%
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Fig. 2. Survival without local recurrence. This Kaplan-
Meier plot is the true representation of how patients with
breast cancer would fare in the first 5 years of their life after
treatment with targeted intraoperative radiation therapy
(TARGIT) during lumpectomy or external beam radiation
therapy (EBRT) with respect to local control. Censoring is
done at the point of last follow-up or withdrawal. For any
patient, her chance of being alive without local recurrence
can be read from this plot. The 5-year survival without local
recurrence: TARGIT: 93.9% (95% CI 90.9-95.9); EBRT:
92.5% (95% CI 89.7-94.6), PZ.35.Noninferiority
We concluded (1, 2) that TARGIT-IORT was noninferior to
external beam radiation therapy (EBRT). Yet, the authors
allege that we claimed that the 2 treatments were equiva-
lent, suggesting that they may not fully understand the basis
of the trial design. In a noninferiority trial, if the difference
between the treatments being tested (and its upper confi-
dence limit) is less than a preset noninferiority margin, the
treatments are considered noninferior even if the difference
is “statistically significant” according to a log-rank test
(Fig. 1). Furthermore, we recommended that TARGIT
should be used during the initial lumpectomy, as in the
prepathology stratum (not subgroup), where the difference
between the 2 treatments was undoubtedly not statistically
significant (PZ.31). Finally, survival without localrecurrence, where deaths are not censored, in line with
recommendations by the FDA and elsewhere (4, 5), is not
statistically different between the 2 arms (Fig. 2).
Table 1 Results of randomised trials comparing radiation therapy with no radiation therapy
Characteristic CALGB BASO 2 PRIME II TARGIT-A prepathology
Number 636 1135 1326 1625
Age (y) 70 65 65 45
T size 2 cm 2 cm 2 cm Small T2,
preferably 3.5 cm
Grade Grade 1 Grade 1 or Grade 2 No restriction
Nodes Negative Negative Negative No restriction
LV invasion Negative Negative No restriction
ER status Positive Positive Positive No restriction
5-year LR 4% vs 1%
Stat Sig.
6% vs 2%
Stat Sig.
4.1% vs 1.3%
Stat Sig.
2.1% vs 1.1% overall
1.4% vs 1.1% if ER Positive
Both Not Statistically Significant
5-year LR in experimental arm 1 in 25 1 in 17 1 in 25 1 in 48 overall
1 in 71 if ER positive
Abbreviations: BASOZ British Association of Surgical Oncology; CALGBZ Cancer And Leukemia Group B (CALGB); ERZ estrogen receptor;
LR Z local recurrence; LV Z Lympho-Vascular; PRIME Z Post-operative Radiotherapy In Minimum-risk Elderly; TARGIT Z TARGeted Intra-
operative radioTherapy.
Bearing in mind the caveats of comparisons between trials, these data suggest that despite having worse prognosis cancers in the TARGIT-A trial, local
control with TARGIT during lumpectomy was excellent and clearly better than “no radiation therapy.”
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solute difference in local recurrence is very conservative
and is validated in patient preference studies (6-8). It is
much smaller than the 7.5% margin of the ELectron
IntraOperative radioTherapy (ELIOT) trial and lower than
the difference considered “acceptable” by the Cancer And
Leukemia Group B (CALGB) (5% difference) and Post-
operative Radiotherapy In Minimum-risk Elderly PRIME II
studies (3% difference). At this boundary, TARGIT is
noninferior to EBRT (Pnoninferiority<.00001). Within the
trial of 3451 patients, the first 1222 patients have a median
follow-up time of 5-years; the safety, efficacy, and non-
inferiority results in these 1222 patients were similar to
those seen in all patients, as shown in Table 3 of Vaidya
et al (1). The Appendix gives details of other arithmetic and
factual errors of Hepel and Wazer, including those of
Haviland et al (9), whom they cite.
Pragmatic
TARGIT-A is a pragmatic randomized controlled trial: it
seeks to address the question “what is the efficacy and safety
of the TARGIT technique if used in clinical practice.”
TARGIT is meant to be used within a risk-adapted approach
designed to enable the addition of conventional EBRT if
additional risk factors come to light postoperatively. This
approach reflects the real-world scenario and avoids the
“one size fits all” ideology. Thus, within the trial, patients
randomized to TARGIT who were given additional EBRT
were not “protocol deviations” or “crossovers” but were
being treated correctly, as per protocol.
TARGIT alone was effective as well
The authors suggest that the additional EBRT obscured any
difference between TARGIT and EBRT. e-Table 2 inVaidya et al (2) shows how patients who received only
TARGIT in the prepathology stratum had relatively poor
prognosis cancers but had excellent local control (97.3%),
which was not dissimilar to the whole TARGIT arm
(97.9%).Stratification
The authors wrongly state that the prepathology (TARGIT
simultaneous with lumpectomy) and postpathology
(delayed TARGIT) strata were subgroups. They were
not. The protocol (10) (http://www.nets.nihr.ac.uk/projects/
hta/076049) specified stratification before randomization to
accommodate different practices in the participating sites.
Direct comparison between the 2 strata is not valid be-
cause patients were not randomly allocated between the 2
strata (2).Only as good as “no radiation therapy”?
Table 1 gives results of randomized trials testing the effect of
completely omitting radiation therapy (11-13). One in every
17 to 25 of even the most stringently selected low-risk pa-
tients would have a local recurrence if radiation therapy were
omitted (10-12). By contrast, when TARGIT is given during
lumpectomy, local recurrence is rare: 1 in 48, and a reduction
to 1 in 71 (ie, 1.4%) when just a single selection criterion
(estrogen receptor positivity) is applied. This is despite the
fact that TARGIT-A trial eligibility was not limited to “good
prognosis” cases, as detailed in the Appendix. Would clini-
cians and patients really wish to completely omit radiation
therapy in anyone who would have been eligible for the
TARGIT-A trial (ie, 45 years old with a unifocal invasive
ductal carcinoma 3.5 cm in size)? Surely not.
P<.001
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Fig. 3. Demonstration of how the reduction in local recurrence by radiation therapy occurs only in the first 5 years, most of
the effect being already seen in the first 2 to 3 years. The top 2 figures are Kaplan-Meier plots from the landmark National
Surgical Adjuvant Breast and Bowel Project (NSABP) B06 (17) (left) and the Swedish trial (right) of radiation therapy (XRT)
versus no radiation therapy after lumpectomy (18). The bottom half shows the data from the Swedish trial expressed as
hazard of local recurrence of radiation therapy versus no radiation therapy from the same Swedish trial. On the left are the
smoothened hazard plots and on the right the absolute values of hazard ratios taken from Wickberg et al (19), again showing
that almost all the reduction in recurrence by radiation therapy is in the first 5 years.
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The peak hazard of recurrence of breast cancer is in the first 2
to 3 years. Vitally, the effect of radiation therapy on localTable 2 Percentage increase in the rate of major coronary
events per Gray, according to time since radiation therapy
Time since
radiation
therapy (y)
No. of
case
patients
No. of
control
individuals
Increase in rate of
major coronary events:
% increase/Gy (95% CI)
0-4 206 328 16.3 (3.0-64.3)
5-9 216 296 15.5 (2.5-63.3)
10-19 323 388 1.2 (2.2 to 8.5)
20 218 193 8.2 (0.4-26.6)
Abbreviation: CI Z confidence interval. Data taken from Darby
et al, Risk of ischemic heart disease in women after radiation therapy
for breast cancer (N Engl J Med 2013; 368:987-998).recurrence is limited to the first 5 years, with most of the
radiation therapy effect already seen in the first 2 to 3 years
(14, 15) (Fig. 3). Thus, local recurrence between 5 and
25 years is no more frequent even in nonirradiated patients
compared with those who have received radiation therapy
(14-16). The TARGIT-A trial includes 3451 patients with a
median follow-up time of 2.5 years and 1222 patients with a
median follow-up time of 5 years; therefore, the available
follow-up time amply covers the period of risk and also the
benefit from radiation therapy. It thus gives complete confi-
dence for the use of TARGIT in clinical practice.
Nonebreast cancer deaths
TARGIT-IORT with Intrabeam delivers almost no dose
to the heart (17). As it happens, the finding of reduced
nonebreast cancer mortality with TARGIT (18) is
TARGIT-A international multi-centre trial included 3451 women randomised to receive TARGIT or EBRT. These figures are created by
applying 5-year Kaplan-Meier estimates of survival without local recurrence to 1000 women having breast conserving therapy in the
two trial arms. Distant or regional disease not shown: there was no difference seen between TARGIT and EBRT. 
There was no statistically significant difference in survival without local recurrence
What happened to women with early breast cancer,
treated with TARGIT during lumpectomy compared with those treated with EBRT,
over the first 5 years?
1000 women randomised to TARGIT 1000 women randomised to EBRT
939 women alive without local recurrence
20 women alive after treatment of local recurrence
1 woman died after local recurrence
40 women died
925 women alive without local recurrence
1 dot = 1 woman
10 women alive after treatment of local recurrence
1 woman died after local recurrence
64 women died
Fig. 4. Pictogram to help patients and doctors make a shared, well-informed decision. EBRT Z external beam radiation
therapy; TARGIT Z targeted intraoperative radiation therapy.
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mortality from other cancers (19) and cardiovascular dis-
ease (20). Contrary to the popular notion, the increased
incidence of major coronary events (myocardial infarction,
coronary revascularization, or death of ischemic heart dis-
ease) becomes evident in the first 5 years after radiation
therapy (Table 2) (20). Hepel and Wazer claim that the
difference in nonebreast cancer deaths (TARGIT 17 vs
EBRT 35) (1) will disappear with longer follow-up times
because in their view, it has arisen from a baseline imbal-
ance: allegedly more women with premorbid cardiac con-
ditions were inadvertently randomized to the EBRT arm.
But this is surely perverse: to equalize the deaths with
longer follow-up times, the next 52 deaths would need to
be in the ratio of TARGIT 35 versus EBRT 17, which is
highly improbable if women in the TARGIT arm are pre-
sumed to have had a lower baseline risk of nonebreast
cancer deaths!
A more plausible explanation is the following: about a
third of the 2.1% absolute difference in nonebreast cancer
mortality (0$6%) was from cardiac causes. This small in-
crease in nonebreast cancer mortality might have beenuncovered early because of the otherwise excellent
outcome from breast cancer (5-year mortality 2.2%). In
older trials, such a small but lethal effect might have
been masked until the high breast cancer mortalitydeg,
30% at 5 years in the CRC1 trial (21)ddiminished in later
years.
Small detrimental effects of treatments have become
much more important today, when mortality from the dis-
ease for many women diagnosed now is relatively low, so
the potential hazards of overtreatment become ever more
important.The study is not flawed
The TARGIT-A trial passed a rigorous peer review
including statistical assessment before it was published in
The Lancet on 2 separate occasions (2010 and 2014). The
authors state that Professor Jack Cuzick was the “initial”
chair of the Data Monitoring Committee (DMC). The fact
is that he was the first and only chair. The DMC were privy
to all the unblinded data and approved the formal Statistical
Vaidya et al. International Journal of Radiation Oncology  Biology  Physics496Analysis Plan and all the analyses. Their remit ended when
the trial concluded in June 2012. The DMC were thanked
and dissolved, nearly a year later. Professor Jack Cuzick did
not resign (22), and no letter of resignation was received.
Adoption and financial implications
A decision analytic framework based on the consequences
of early adoption if the results do not hold, and the op-
portunity cost of late adoption if the results do hold (23),
strongly supports adoption of TARGIT (23). TARGIT has
better health care value: noninferior results and higher pa-
tient value, requiring less time, fewer out-of-pocket ex-
penses, and fewer resources overall (estimated savings of at
least $1.2 billion in the United States alone over 5 years).
The fact that TARGIT saves money within the health care
system (24, 25) should be taken as a bonus rather than a
threat in the modern era of increasing health care costs.
Conclusions
The data from this large randomized international clinical
trial do indeed challenge the current paradigm of whole
breast radiation therapy for the majority of breast cancer
patients. That clearly adds to the discomfiture of our critics.
Yet, we remain concerned about the adoption of new
techniques such as balloon brachytherapy that are untested
by the rigors of a randomized controlled trial (including
those promoted by the authors [26] http://www.accuboost.
com).
The level 1 randomized evidence produced by the
TARGIT-A trial shows that TARGIT-IORT with Intrabeam
during lumpectomy, which is very convenient for the pa-
tient, is effective and has fewer side effects than the con-
ventional alternative of whole breast radiation therapy.
Hepel and Wazer clearly accept that “5-year LF (local
failure) rate for prepathology TARGIT is not statistically
different from EBRT” (3), in which case they should not
object to TARGIT, bearing in mind the much greater con-
venience for patients completing their entire local treatment
during surgery rather than the significantly more onerous
and expensive postoperative treatment or procedures. Pa-
tients have every right to be offered an informed choice,
and Figure 4 may be used to facilitate a shared decision.
References
1. Vaidya JS, Wenz F, Bulsara M, et al. Risk-adapted targeted intra-
operative radiotherapy versus whole-breast radiotherapy for breast
cancer: 5-year results for local control and overall survival from the
TARGIT-A randomised trial. Lancet 2014;383:603-613.
2. Vaidya JS, Wenz F, Bulsara M, et al. Radiotherapy for breast cancer,
the TARGIT-A trial - Authors’ reply. Lancet 2014;383:1719-1720.
3. Hepel J, Wazer DE. A flawed study should not define a new standard
of care. Int J Radiat Oncol Biol Phys 2015;91:255-257.
4. Lamont EB, Herndon JE 2nd, Weeks JC, et al. Measuring disease-free
survival and cancer relapse using Medicare claims from CALGBbreast cancer trial participants (companion to 9344). J Natl Cancer
Inst 2006;98:1335-1338.
5. United States Department of Health and Human Services FDA.
Guidance for industry: Clinical trial endpoints for the approval of
cancer drugs and biologics. May 2007.
6. Alvarado MD, Conolly J, Park C, et al. Patient preferences regarding
intraoperative versus external beam radiotherapy following breast-
conserving surgery. Breast Cancer Res Treat 2014;143:135-140.
7. Corica T, Joseph D, Saunders C, et al. Intraoperative radiotherapy for
early breast cancer: Do health professionals choose convenience or
risk? Radiat Oncol 2014;9:33.
8. Corica T, Nowak A, Saunders C, et al. Patient preferences for adjuvant
radiotherapy in early breast cancer: An Australian sub-study of the
international TARGIT trial. Eur J Cancer 2012;48(Suppl 1):S187.
Abstract 482.
9. Haviland JS, A’Hern R, Bentzen SM, et al. Radiotherapy for breast
cancer: The TARGIT-A trial. Lancet 2014;383:1716-1717.
10. The TARGIT-A trial protocol. http://www.nets.nihr.ac.uk/projects/hta/
076049 and http://www.targit.org.uk. Accessed May 11, 2015.
11. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus
tamoxifen with or without irradiation in women age 70 years or older
with early breast cancer: Long-term follow-up of CALGB 9343. J Clin
Oncol 2013;31:2382-2387.
12. Blamey RW, Bates T, Chetty U, et al. Radiotherapy or tamoxifen after
conserving surgery for breast cancers of excellent prognosis: British
Association of Surgical Oncology (BASO) II trial. Eur J Cancer 2013;
49:2294-2302.
13. Kunkler IH, Williams LJ, Jack WJ, et al. Breast-conserving surgery
with or without irradiation in women aged 65 years or older with early
breast cancer (PRIME II): A randomised controlled trial. Lancet Oncol
2015;16:266-273.
14. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a
randomized trial comparing total mastectomy, lumpectomy, and
lumpectomy plus irradiation for the treatment of invasive breast can-
cer. N Engl J Med 2002;347:1233-1241.
15. Wickberg A, Holmberg L, Adami HO, et al. Sector resection with or
without postoperative radiotherapy for stage I breast cancer: 20-year
results of a randomized trial. J Clin Oncol 2014;32:791-797.
16. Wickberg A, Holmberg L, Adami HO, et al. Reply to A. Levy et al. J
Clin Oncol 2014;32:3340.
17. Aziz MH, Schneider F, Clausen S, et al. Can the risk of secondary
cancer induction after breast conserving therapy be reduced using
intraoperative radiotherapy (IORT) with low-energy x-rays? Radiat
Oncol 2011;6:174.
18. Vaidya JS, Bulsara M, Wenz F. Ischemic heart disease after breast
cancer radiotherapy. N Engl J Med 2013;368:2526-2527.
19. Grantzau T, Overgaard J. Risk of second non-breast cancer after
radiotherapy for breast cancer: A systematic review and meta-analysis
of 762,468 patients. Radiother Oncol 2015;114:56-65.
20. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease
in women after radiotherapy for breast cancer. N Engl J Med 2013;
368:987-998.
21. Houghton J, Baum M, Haybittle JL. Role of radiotherapy following
total mastectomy in patients with early breast cancer: The Closed
Trials Working Party of the CRC Breast Cancer Trials Group. World J
Surg 1994;18:117-122.
22. Cuzick J. Radiotherapy for breast cancer: The TARGIT-A trial. Lancet
2014;383:1716.
23. Esserman LJ, Alvarado MD, Howe RJ, et al. Application of a decision
analytic framework for adoption of clinical trial results: Are the data
regarding TARGIT-A IORT ready for prime time? Breast Cancer Res
Treat 2014;144:371-378.
24. Alvarado M, Ozanne E, Mohan A, et al. Cost-effectiveness of intra-
operative radiation therapy for breast conservation. J Clin Oncol 2011;
29(Suppl). abstr 6081.
25. Vaidya JS, Tobias JS, Baum M, et al. Intraoperative radiotherapy for
breast cancer. Lancet Oncol 2004;5:165-173.
26. Accuboost. http://www.accuboost.com.
Volume 92  Number 3  2015 Pride, prejudice, or science: the TARGIT-A trial 49727. Piaggio G, Elbourne DR, Pocock SJ, et al. Reporting of noninferiority
and equivalence randomized trials: Extension of the CONSORT 2010
statement. JAMA 2012;308:2594-2604.
28. Smits PC, Hofma S, Togni M, et al. Abluminal biodegradable polymer
biolimus-eluting stent versus durable polymer everolimus-eluting stent
(COMPARE II): A randomised, controlled, non-inferiority trial. Lan-
cet 2013;381:651-660.
29. Tunes da Silva G, Logan BR, Klein JP. Methods for equivalence and
noninferiority testing. Biol Blood Marrow Transplant 2009;15(1
Suppl):120-127.
30. Vaidya JS, Wenz F, Bulsara M, et al. Case selection for targeted
intraoperative radiotherapy (TARGIT). Eur J Cancer 2013;49:S451.
31. Vaidya JS, Benson JR, Tobias JS. Targeted intraoperative radiotherapy
for breast cancer: Not all cancers in the breast will grow. In:
Benson JR, Gui GPH, Tuttle T, editors. Early Breast Cancer: From
Screening to Multidisciplinary Management. 3rd ed. London: CRC
Press, Taylor Francis Group; 2013. p. 455-463.
Appendix
Arithmetic errors of critics such as Hepel and
Wazer
Hepel and Wazer cite Haviland et al (6), who disregard that
noninferiority is not tested for the single snapshot point
estimates of “5-year recurrence rate”; these do not represent
actual events but only estimates, and using these values as
if they are simple proportions leads to erroneous calcula-
tions. Noninferiority is tested using the actual number of
recurrences that occur in the follow up period.
Haviland and colleagues state that “Based on the 5-year
estimates for local recurrence of 3.3% (95% CI 2.1-5.1)
after intra operative radiation therapy and 1.3% (0.7-2.5)
after EBRT, the estimated hazard ratio (HR) is 2.56. The
standard error of the HR can also be estimated (2), sug-
gesting an upper limit of 5.47 for its 1-sided 95% CI. In
view of the 1.3% local recurrence rate after EBRT, the local
recurrence rate after intraoperative radiation therapy could
therefore be as high as 7.1%, far exceeding the predefined
noninferiority limit.” This calculation by Haviland and
colleagues that the upper 95% CI using point estimates is
7.1%, when the raw dataedriven real value is 5.1%, is
obviously inaccurate and demonstrates the flaws of using
multiple nested assumptions. Read their paragraph care-
fully: the real 95% CI based on raw data is given in the first
sentence, and then they derive a hazard ratio and estimate it
again and believe the latter rather than the original, wrongly
influenced by their own estimates.Finally, for noninferiority testing, the convention is to
use 90% CI rather than 95% as suggested by Professor Jack
Cuzick in his letter (22) and elsewhere (27-29).
Three examples of factually incorrect statements
by Hepel and Wazer
1. Hepel and Wazer allege that there was no difference in
nonebreast cancer mortality in the postpathology stra-
tum. This is not strictly true. Although there were fewer
total deaths, the ratio was still in favor of TARGIT
(TARGIT 5; EBRT 8).
2. They wrongly state that “the 5-year LF rate for ‘pre-
pathology’ TARGIT (2.5%) was higher [sic] than that of
‘postpathology’ (5.4%).” First, this is obviously erro-
neous (2.5% is not higher than 5.4%). Second, the 2
strata were not formally compared, so there is no basis
for such a statement anyway. Third, the actual numbers
are also wrong: in reality, the prepathology TARGIT
recurrence rate is 2.1%, not 2.5%, and it is not statisti-
cally different from EBRT (1.1%).
3. They claim that TARGIT failed because the LF rate of
TARGIT was higher than that of EBRT. However, as
explained in The Lancet (2), the difference between
TARGIT and EBRT (PZ.042) is in fact statistically not
significant because we prespecified P<.01 as the cutoff
for statistical significance because of our initial a spend
in 2010.TARGIT-A trial eligibility was not limited to “good
prognosis” cases
In the TARGIT-A trial, 85% of patients were younger than
70 years, and a large number had adverse prognostic fac-
tors: node positive (nZ502), ER or PgR negative (nZ554),
grade 3 (nZ459), or >2 cm (nZ397). Only hormone re-
ceptor status made any difference to the outcome (30).
More than 60% of cases in the TARGIT-A trial would be
considered “unsuitable” or “cautionary” by the ASTRO
criteria (31). Only 17.5% of patients in the TARGIT-A trial
prepathology stratum would have been eligible for the
PRIME2 trial; all others (82.5%) had “worse” prognosis
cancers.
